The Significance of Tumor-infiltrating Lymphocytes (TILs) in Histopathological Grading of Invasive Breast Carcinomas

  • Rahmiany Syam Department of Anatomic Pathology, Faculty of Medicine, Hasanuddin University
  • Upik A. Miskad Department of Anatomic Pathology, Faculty of Medicine, Hasanuddin University
  • Andi Alfian Zainuddin Department of Public Health, Faculty of Medicine, Hasanuddin University
  • Ni Ketut Sungowati Department of Anatomic Pathology, Faculty of Medicine, Hasanuddin University
  • Gunawan Arsyadi Department of Anatomic Pathology, Faculty of Medicine, Hasanuddin University
  • Berti Nelwan Department of Anatomic Pathology, Faculty of Medicine, Hasanuddin University
Keywords: TILs, histopathological grading, invasive breast carcinoma


Breast cancer is the leading cause of cancer death in women worldwide with high incidence rate. Invasive breast carcinoma is the most common form of breast cancer. Prognosis and survival rate of the patient is related with histopathological grading of the invasive breast carcinoma. Tumor-infiltrating lymphocytes (TILs) have been reported to be associated with patient clinical outcomes in a number of different malignant tumors. We studied the expression of TILs in invasive breast carcinoma using Hematoxylin Eosin (HE) staining. We studied the expression of are tumor-infiltrating lymphocytes (TILs) in paraffin block of tissue biopsy from breast tumor specimens. Immunohistochemistry was used to assess the expression of TILs in tumor breast tissue from 80 samples. Univariate and bivariate analyses assessed outcomes according to the expression of TILs in different histopathological grading. Of the 80 tumor specimens, 36 (45 %) of samples have high grade of TILs and 44 (55 %). On bivariate analysis, there were significant differences in the expression of TILs lymphocytes between well, moderately and poorly differentiated invasive breast carcinoma, respectively (p< 0.0001). As a conclusion; we found that the severity of invasive breast carcinoma differentiation is directly related to the degree of TILs expression.


L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA. Cancer J. Clin., vol. 65, no. 2, pp. 87–108, 2015, doi: 10.3322/caac.21262.

M. Papadimitriou et al., “Nuclear Grade Plus Proliferation Grading System for Invasive Ductal Carcinoma of the Breast: Validation in a Tertiary Referral Hospital Cohort,” Am. J. Clin. Pathol., vol. 144, no. 6, pp. 837–843, Dec. 2015, doi: 10.1309/AJCPVH6FED2ZATUP.

K. Jakubowska, W. Kisielewski, L. Kańczuga-Koda, M. Koda, and W. Famulski, “Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma,” Oncol. Lett., vol. 14, no. 6, pp. 6421–6432, Dec. 2017, doi: 10.3892/ol.2017.7013.

A. Zgura, L. Galesa, E. Bratila, and R. Anghel, “Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer,” Mædica, vol. 13, no. 4, pp. 317–320, Dec. 2018, doi: 10.26574/maedica.2018.13.4.317.

“Cellular and Molecular Immunology - 9th Edition.” (accessed Oct. 22, 2021).

A. Cimino-Mathews, J. B. Foote, and L. A. Emens, “Immune targeting in breast cancer,” Oncol. Williston Park N, vol. 29, no. 5, pp. 375–385, May 2015.

H. R. Ali et al., “Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients,” Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., vol. 25, no. 8, pp. 1536–1543, Aug. 2014, doi: 10.1093/annonc/mdu191.

S. Loi et al., “Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 37, no. 7, pp. 559–569, Mar. 2019, doi: 10.1200/JCO.18.01010.

R. Salgado et al., “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014,” Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., vol. 26, no. 2, pp. 259–271, Feb. 2015, doi: 10.1093/annonc/mdu450.

Y. Iseki et al., “A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections,” PloS One, vol. 13, no. 4, p. e0192744, 2018, doi: 10.1371/journal.pone.0192744.

M. Pujani, H. Jain, V. Chauhan, C. Agarwal, K. Singh, and M. Singh, “Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage,” Breast Dis., vol. 39, no. 2, pp. 61–69, 2020, doi: 10.3233/BD-200442.

I. Kolarov-Bjelobrk et al., “Clinical Relevance of Determination of Tumour Infiltrating Lymphocytes in Breast Carcinoma,” West Indian Med. J., Mar. 2017, doi: 10.7727/wimj.2017.044.